|
|
减瘤性肾切除在转移性肾细胞癌治疗中的地位
|
Abstract:
减瘤性肾切除(cytoreductive nephrectomy, CN)是指尽可能切除转移性肾细胞癌患者的原发灶。晚期转移性肾癌的治疗目前仍是一大难点，治疗方案包括全身治疗和全身治疗联合姑息性手术，减瘤性肾切除主要针对肾肿瘤原发灶的治疗，选择合适的病例及手术时机，对于预后具有重要意义和影响。
Cytoreductive nephrectomy (CN) refers to removing the primary lesion of patients with metastatic renal cell carcinoma as far as possible. At present, the treatment of advanced metastatic renal can-cer is still a major difficulty, and the treatment plan includes systemic therapy and systemic thera-py combined with palliative surgery. Tumor cytoreductive nephrectomy is mainly aimed at the treatment of primary renal tumor. The selection of appropriate cases and surgical timing is of great significance and influence on prognosis.
| [1] | Steven, C., et al. (2015) Campbell-Walsh Urology. 11th Edition, Elsevier, Amsterdam, 1320-1321. |
| [2] | Capitanio, U., et al. (2019) Epidemiology of Renal Cell Carcinoma. European Urology, 75, 74-84.
https://doi.org/10.1016/j.eururo.2018.08.036 |
| [3] | Tahbaz, R., et al. (2018) Prevention of Kidney Cancer Incidence and Recurrence: Lifestyle, Medication and Nutrition. Current Opinion in Urology, 28, 62-79. https://doi.org/10.1097/MOU.0000000000000454 |
| [4] | Sung, H., Ferrlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. |
| [5] | Flanigan, R.C. and Yonover, P.M. (2001) The Role of Radical Nephrectomy in Metastatic Renal Cell Carcinoma. Seminars in Urologic Oncology, 19, 98-102. |
| [6] | Escudier, B., Szczylik, C., Hutson, T.E., Demkow, T., et al. (2009) Randomized Phase II Trial of First-Line Treatment with Sorafenib versus Interferon Alfa-2ain Patients with Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 27, 1280-1289. https://doi.org/10.1200/JCO.2008.19.3342 |
| [7] | Motzer, R.J., Hutson, T.E., Tomczak, P., et al. (2007) Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. The New England Journal of Medicine, 256, 115-124. https://doi.org/10.1056/NEJMoa065044 |
| [8] | Motzer, R.J., Escudier, B., Oudard, S., et al. (2008) Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial. The Lancet, 372, 449-456.
https://doi.org/10.1016/S0140-6736(08)61039-9 |
| [9] | Hudes, G., Carducci, M., Tomczak, P., et al. (2007) Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 356, 2271-2281. https://doi.org/10.1056/NEJMoa066838 |
| [10] | Massari, F., Di Nunno, V., Gatto, L., et al. (2018) Should CARMENA Really Change Our Attitude toward Cytoreductive Nephrectomy Inmetastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Tar-geted Oncology, 13, 705-714.
https://doi.org/10.1007/s11523-018-0601-2 |
| [11] | Conti, S.L., Thomas, I.C., Hagedorn, J.C., et al. (2014) Utilization of Cytoreductive Nephrectomy and Patient Survival in the Targeted Therapy Era. International Journal of Cancer, 134, 2245-2252. https://doi.org/10.1002/ijc.28553 |
| [12] | Choueiri, T.K., Xie, W., Kollmannsberger, C., et al. (2011) The Impact of Cytoreductive Nephrectomy on Survival of Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. Journal of Urology, 185, 60-66. https://doi.org/10.1016/j.juro.2010.09.012 |
| [13] | Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., et al. (2001) Ne-phrectomy Followed by Interferon Alfa-2b Compared with Interferonalfa-2b Alone for Metastatic Renal-Cell Cancer. The New England Journal of Medicine, 345, 1655-1659.
https://doi.org/10.1056/NEJMoa003013 |
| [14] | Mickisch, G.H., Garin, A., van Poppel, H., et al. (2001) Radical Ne-phrectomy plus Interferon-Alfa-Based Immunotherapy Compared with Interferon Alfa Alone in Metastatic Renal-Cell Carcinoma: A Randomised Trial. The Lancet, 358, 966-970. https://doi.org/10.1016/S0140-6736(01)06103-7 |
| [15] | Motzer, R.J., Bukowski, R.M., Figlin, R.A., et al. (2008) Prognostic Nomogram for Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Cancer, 113, 1552-1558. https://doi.org/10.1002/cncr.23776 |
| [16] | Wood, C.G. (2001) Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Out-come. Clinical Cancer Research, 13, 697s-702s. https://doi.org/10.1158/1078-0432.CCR-06-2109 |
| [17] | Pierorazio, P.M., McKiernan, J.M., McCann, T.R., et al. (2007) Outcome after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Is Predicted by Fractional Percentage of Tumour Volume Removed. BJU International, 100, 755-759. https://doi.org/10.1111/j.1464-410X.2007.07108.x |
| [18] | Barbastefano, J., Garcia, J.A., Elson, P., et al. (2010) As-sociation of Percentage of Tumour Burden Removed with Debulking Nephrectomy and Progression Free Survivalin Pa-tients with Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor Targeted Therapy. BJU In-ternational, 106, 1266-1269.
https://doi.org/10.1111/j.1464-410X.2010.09323.x |
| [19] | Hanna, N., Sun, M., Meyer, C.P., et al. (2016) Survival Analyses of Patients with Metastatic Renal Cancer Treated with Targeted Therapy with or without Cytoreductive Ne-phrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 34, 3267-3275. https://doi.org/10.1200/JCO.2016.66.7931 |
| [20] | Méjean, A., et al. (2018) Sunitinib Alone or after Nephrectomy in Metastatic Renal Cell Carcinoma. The New England Journal of Medicine, 379, 417-427. https://doi.org/10.1056/NEJMoa1803675 |
| [21] | Kutikov, A., Uzzo, R.G., Caraway, A., et al. (2010) Use of Sys-temic Therapy and Factors Affecting Survival for Patients Undergoing Cytoreductive Nephrectomy. BJU International, 106, 218-223.
https://doi.org/10.1111/j.1464-410X.2009.09079.x |
| [22] | Abdollah, F., Sun, M., Thuret, R., et al. (2011) Mortality and Morbidity after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study. Annals of Surgical Oncology, 18, 2988-2996.
https://doi.org/10.1245/s10434-011-1715-2 |
| [23] | Maxwell, N.J., Saleem Amer, N., Rogers, E., et al. (2007) Renal Artery Embolisation in the Palliative Treatment of Renal Carcinoma. The British Journal of Radiology, 80, 96-102. https://doi.org/10.1259/bjr/31311739 |
